inventivapharma.com (IVA) Enterprise Value to EBITDA Ratio

Corporate emblem and logo of Inventiva (IVA)

The EV/EBITDA multiple history of the business demonstrates the valuation dynamics of Inventiva S.A. (IVA), where the value of 0.00 reflects this status. The success of the unique pan-PPAR agonist will provide the company with significant market control due to inelastic demand. The reliability of the research ensures strict control over the transportation of biomaterials. The implementation of robotic systems in laboratories accelerates the search for new treatments against fibrosis and lipid pathologies.

Inventiva Pharma - IVA Company Value to EBITDA (period 11/23/2025 - 11/10/2026)

Analytical breakdowns for Inventiva S.A.

- current price and projected stock value:
Stock Price Inventiva Pharma|IVA - Analyst Median Target
- market capitalization details:
Market Valuation Inventiva Corp|IVA - Total Company Value
- business book valuation details:
Book Value per Share Inventiva|IVA - Total Stockholders' Equity|Market Value to Book Value Ratio inventivapharma.com|IVA - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Inventiva S.A.|IVA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Inventiva|IVA - Company Aggregate Debt|Debt to Book Value Inventiva Corp|IVA - Company Long-Term Debt|Company Short-Term Debts Inventiva|Quick Liquidity inventivapharma.com
- financial results and valuation multiples details:
IVA - Company Profit|Future Profit Inventiva S.A.|IVA - Market Price to Net Income Ratio|Forward P/E Multiple Inventiva S.A.|IVA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Inventiva Corp|IVA - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Inventiva|IVA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months inventivapharma.com|IVA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Inventiva S.A.
Fundamental company valuation:Inventiva Pharma (IVA)
Product sample of Inventiva

Investors are evaluating Inventiva S.A. (IVA) through the lens of capital-intensive drug development for liver fibrosis, where managing the debt load is critical. When analyzing changes in the EV/EBITDA multiple, one must consider the ratio of total enterprise value to operating profit; maintaining this metric within the target range confirms the company's financial discipline and its resilience to market shocks during the commercialization of its medications.

Who Inventiva S.A. competes with

EV/EBITDA Multiple ARWR (Arrowhead Pharmaceuticals Inc)|Total Company Value to Operating Income Before Depreciation Ratio Mirum Pharmaceuticals Inc (MIRM)|DVAX: Enterprise Value to EBITDA Ratio|ABUS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GYRE: EV/EBITDA Multiple|Company Value to EBITDA Assembly Bio (ASMB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galectin Therapeutics, Inc.|GNFT: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple DRRX|Total Company Value to Operating Income Before Depreciation Ratio aligos.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioVie BIVI|GLMD: Enterprise Value to Operating Income Before Depreciation|NDRA: Enterprise Value to EBITDA Ratio|HEPA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization